直接作用抗病毒药物治疗丙型肝炎病毒感染：100%治愈？
Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?
机构信息
Department of Hepatology, Centre de Recherche sur l'Inflammation, Viral Hepatitis INSERM, UMR 1149, AP-HP Hôpital Beaujon, Université Paris Diderot, Clichy, France.
Department of Pediatrics, Center for AIDS Research, Emory University School of Medicine, Atlanta, GA, USA.
出版信息
Liver Int. 2018 Feb;38 Suppl 1(Suppl 1):7-13. doi: 10.1111/liv.13673.
Abstract
Around 71 million people are chronically infected with HCV worldwide. HCV antiviral drug development has been remarkable. The availability of pangenotypic direct-acting antivirals with excellent efficacy and good tolerability profiles offer a unique opportunity to achieve HCV elimination worldwide. IFN-free DAA combinations can now cure HCV in more than 95% of patients with HCV infection after 8-12 weeks of treatment. Programmes to eliminate HCV must include increased screening (risk-based and universal), linkage to care, as well as increased access to treatment worldwide. In this paper, we will review the available data on recently approved direct-acting antiviral agents, with sustained virological response that reaches almost 100%.
摘要
全球约有 7100 万人慢性感染 HCV。HCV 抗病毒药物的研发取得了显著成就。具有优异疗效和良好耐受性的泛基因型直接作用抗病毒药物的出现，为全球范围内实现 HCV 消除提供了独特的机会。无干扰素 DAA 联合方案现在可以在 8-12 周的治疗后治愈超过 95%的 HCV 感染患者。消除 HCV 的计划必须包括增加筛查（基于风险和普遍筛查）、与护理的联系，以及在全球范围内增加治疗机会。在本文中，我们将回顾最近批准的直接作用抗病毒药物的现有数据，这些药物的持续病毒学应答率几乎达到 100%。
相似文献
1
Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?直接作用抗病毒药物治疗丙型肝炎病毒感染：100%治愈？
Liver Int. 2018 Feb;38 Suppl 1(Suppl 1):7-13. doi: 10.1111/liv.13673.
2
Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.直接作用抗病毒治疗在 HCV 基因 1 型感染中的疗效、安全性和临床结局：来自西班牙真实世界队列的研究结果。
J Hepatol. 2017 Jun;66(6):1138-1148. doi: 10.1016/j.jhep.2017.01.028. Epub 2017 Feb 9.
3
A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY).一项在有或无 HIV 患者中用索磷布韦/维帕他韦/沃西拉韦进行 HCV 再治疗的安全性和疗效的初步研究（RESOLVE 研究）。
J Hepatol. 2019 Sep;71(3):498-504. doi: 10.1016/j.jhep.2019.05.021. Epub 2019 Jun 5.
4
Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses.清除丙型肝炎病毒对 HCV 特异性 CD8+ T 细胞反应的功能和线粒体损伤的影响有限。
J Hepatol. 2019 Nov;71(5):889-899. doi: 10.1016/j.jhep.2019.06.025. Epub 2019 Jul 8.
5
Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.直接作用抗病毒药物和宿主靶向药物时代的慢性丙型肝炎病毒感染的治疗。
J Infect. 2014 Jan;68(1):1-20. doi: 10.1016/j.jinf.2013.08.019. Epub 2013 Sep 4.
6
Treatment of chronic HCV genotype 1 coinfection.慢性丙型肝炎病毒1型合并感染的治疗。
Curr HIV/AIDS Rep. 2015 Sep;12(3):326-35. doi: 10.1007/s11904-015-0278-4.
7
Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.正在接受药物治疗的吸毒者和接受阿片类药物替代治疗者对直接作用抗病毒治疗的反应。
J Hepatol. 2019 Jul;71(1):45-51. doi: 10.1016/j.jhep.2019.02.018. Epub 2019 Mar 8.
8
Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C.固定剂量复方片剂asunaprevir+beclabuvir+daclatasvir 治疗丙型肝炎的疗效和安全性。
Expert Opin Pharmacother. 2020 Feb;21(3):261-273. doi: 10.1080/14656566.2019.1697674. Epub 2020 Jan 8.
9
Treatment of hepatitis C: a systematic review.丙型肝炎的治疗：系统评价。
JAMA. 2014 Aug 13;312(6):631-40. doi: 10.1001/jama.2014.7085.
10
Regimens for the Hepatitis C Treatment-Naive Patient.初治丙型肝炎患者的治疗方案。
Clin Liver Dis. 2015 Nov;19(4):619-27, v. doi: 10.1016/j.cld.2015.06.003. Epub 2015 Aug 7.
引用本文的文献
1
The HCV-Dependent Inhibition of Nrf1/ARE-Mediated Gene Expression Favours Viral Morphogenesis.丙型肝炎病毒依赖的对Nrf1/ARE介导的基因表达的抑制作用有利于病毒形态发生。
Viruses. 2025 Jul 28;17(8):1052. doi: 10.3390/v17081052.
2
National hepatitis B and C estimates for 2021: Measuring Canada's progress towards eliminating viral hepatitis as a public health concern.2021年全国乙肝和丙肝评估：衡量加拿大在消除作为公共卫生问题的病毒性肝炎方面取得的进展。
Can Commun Dis Rep. 2025 Jul 1;51(6-7):223-237. doi: 10.14745/ccdr.v51i67a02. eCollection 2025 Jul.
3
The Role of Direct-Acting Antivirals in Enhancing Quality of Life Among Individuals with Chronic Hepatitis C.直接抗病毒药物在提高慢性丙型肝炎患者生活质量中的作用。
Healthcare (Basel). 2025 Apr 11;13(8):878. doi: 10.3390/healthcare13080878.
4
Asian Perspective on Hepatitis B Virus and Hepatitis C Virus Elimination.亚洲对消除乙型肝炎病毒和丙型肝炎病毒的看法。
Viruses. 2024 Dec 29;17(1):34. doi: 10.3390/v17010034.
5
Outcomes of Direct-Acting Antivirals Versus Interferon-Based Therapy in Chronic Hepatitis C Infection.慢性丙型肝炎感染中直接抗病毒药物与基于干扰素治疗的疗效比较
Cureus. 2024 Dec 17;16(12):e75902. doi: 10.7759/cureus.75902. eCollection 2024 Dec.
6
Efficacy and safety of direct-acting antiviral regimen for patients with hepatitis C virus genotype 2: a systematic review and meta-analysis.直接作用抗病毒方案治疗丙型肝炎病毒基因型 2 患者的疗效和安全性：系统评价和荟萃分析。
BMC Gastroenterol. 2024 Sep 30;24(1):331. doi: 10.1186/s12876-024-03414-5.
7
HIV-1 usurps mixed-charge domain-dependent CPSF6 phase separation for higher-order capsid binding, nuclear entry and viral DNA integration.HIV-1 劫持混合电荷域依赖性 CPSF6 相分离以增强衣壳结合、核进入和病毒 DNA 整合。
Nucleic Acids Res. 2024 Oct 14;52(18):11060-11082. doi: 10.1093/nar/gkae769.
8
Novel Pyrazino[1,2-]indole-1,3(2,4)-dione Derivatives Targeting the Replication of Viruses: Structural and Mechanistic Insights.新型吡嗪并[1,2-]吲哚-1,3(2,4)-二酮衍生物靶向病毒复制：结构和机制见解。
Viruses. 2024 Aug 1;16(8):1238. doi: 10.3390/v16081238.
9
Distinct Characteristic Binding Modes of Benzofuran Core Inhibitors to Diverse Genotypes of Hepatitis C Virus NS5B Polymerase: A Molecular Simulation Study.苯并呋喃核心抑制剂与丙型肝炎病毒 NS5B 聚合酶不同基因型的独特结合模式：分子模拟研究。
Int J Mol Sci. 2024 Jul 23;25(15):8028. doi: 10.3390/ijms25158028.
10
Risk of hepatocellular carcinoma occurrence after antiviral therapy for patients with chronic hepatitis C Infection: a systematic review and meta-analysis.抗病毒治疗慢性丙型肝炎感染患者后肝细胞癌发生的风险：系统评价和荟萃分析。
Hepatol Int. 2024 Oct;18(5):1459-1471. doi: 10.1007/s12072-024-10700-7. Epub 2024 Jul 5.
本文引用的文献
1
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.格卡瑞韦哌仑他韦片治疗 8 或 12 周用于治疗 1 型或 3 型丙型肝炎病毒感染。
N Engl J Med. 2018 Jan 25;378(4):354-369. doi: 10.1056/NEJMoa1702417.
2
Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3.直接作用抗病毒药物初治慢性丙型肝炎的索磷布韦和维帕他韦联合或不联合沃士韦拉帕维：来自 POLARIS 2 和 3 的患者报告结局。
Aliment Pharmacol Ther. 2018 Jan;47(2):259-267. doi: 10.1111/apt.14423. Epub 2017 Nov 27.
3
Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir.新一代丙型肝炎病毒 NS3/4A 蛋白酶抑制剂格卡瑞韦的抗病毒活性和耐药谱。
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01620-17. Print 2018 Jan.
4
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.格卡瑞韦和哌仑他韦治疗丙型肝炎病毒合并严重肾功能损害患者。
N Engl J Med. 2017 Oct 12;377(15):1448-1455. doi: 10.1056/NEJMoa1704053.
5
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.Glecaprevir/Pibrentasvir 治疗 8 或 12 周对无肝硬化的 2、4、5 或 6 型丙型肝炎病毒感染患者的疗效。
Clin Gastroenterol Hepatol. 2018 Mar;16(3):417-426. doi: 10.1016/j.cgh.2017.09.027. Epub 2017 Sep 22.
6
Shortening HCV therapy: science meets public health.缩短丙型肝炎病毒治疗疗程：科学与公共卫生的交汇
Lancet Gastroenterol Hepatol. 2017 Nov;2(11):771-772. doi: 10.1016/S2468-1253(17)30215-7. Epub 2017 Aug 10.
7
Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.索磷布韦/维帕他韦治疗 1-6 型丙型肝炎病毒感染合并代偿期肝硬化或中重度纤维化患者的效果
Liver Int. 2018 Mar;38(3):443-450. doi: 10.1111/liv.13534. Epub 2017 Oct 22.
8
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.索磷布韦、维帕他韦和沃西拉韦治疗既往 HCV 感染。
N Engl J Med. 2017 Jun 1;376(22):2134-2146. doi: 10.1056/NEJMoa1613512.
9
Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons.NS3/4A蛋白酶抑制剂格卡瑞韦和NS5A抑制剂艾尔巴韦对丙型肝炎病毒GT4复制子的抗病毒活性及耐药性分析
Antimicrob Agents Chemother. 2017 Jun 27;61(7). doi: 10.1128/AAC.00363-17. Print 2017 Jul.
10
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.索磷布韦、维帕他韦和沃士韦三者联用治疗慢性丙型肝炎病毒感染患者 8 周的疗效：两项 3 期随机试验。
Gastroenterology. 2017 Jul;153(1):113-122. doi: 10.1053/j.gastro.2017.03.047. Epub 2017 Apr 5.
Zotero 插件